Specific TCR profiles predict clinical outcome of adjuvant EGFR-TKIs for resected EGFR-mutant non-small cell lung cancer.
Si-Yang Maggie LiuCunte ChenYi-Kai ZhangWen-Zhao ZhongYi-Long WuSi-Yang LiuYangqiu LiPublished in: Biomarker research (2023)
In this study, a predictive model was constituted with specific TCR sequences for prognosis prediction and gefitinib benefit in the ADJUVANT-CTONG1104 trial. We provide a potential immune biomarker for EGFR-mutant NSCLC patients who might benefit from an adjuvant EGFR-TKI.
Keyphrases
- small cell lung cancer
- epidermal growth factor receptor
- tyrosine kinase
- advanced non small cell lung cancer
- early stage
- brain metastases
- regulatory t cells
- clinical trial
- lymph node
- randomized controlled trial
- immune response
- phase iii
- phase ii
- prognostic factors
- human health
- chronic myeloid leukemia
- genetic diversity